Unknown PHASE1 INTERVENTIONAL 1-arm NCT01672463

Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients (OKN-007)

Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients

Sponsor: Oblato, Inc.

Interventions OKN-007

Updated 11 times since 2017 Last updated: Mar 28, 2023 Started: Dec 31, 2012 Primary completion: Jan 31, 2023 Completion: Oct 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01672463, this PHASE1 trial focuses on Recurrent Malignant Glioma and remains ongoing. Sponsored by Oblato, Inc., it has been updated 11 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

11 versions recorded

Apr 2025 — Present [monthly]

Unknown PHASE1

Status: Active Not Recruiting → Unknown
Sep 2024 — Apr 2025 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
Apr 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE1
Oct 2021 — Apr 2023 [monthly]

Active Not Recruiting PHASE1

▶ Show 6 earlier versions

Jan 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE1
Apr 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2018 — Apr 2020 [monthly]

Recruiting PHASE1
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE1
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oblato, Inc.

Data source: Oblato, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oklahoma City, United States